BR112012013503A2 - suspensões de nanopartícula contendo polímero de carboxivinila - Google Patents

suspensões de nanopartícula contendo polímero de carboxivinila

Info

Publication number
BR112012013503A2
BR112012013503A2 BR112012013503A BR112012013503A BR112012013503A2 BR 112012013503 A2 BR112012013503 A2 BR 112012013503A2 BR 112012013503 A BR112012013503 A BR 112012013503A BR 112012013503 A BR112012013503 A BR 112012013503A BR 112012013503 A2 BR112012013503 A2 BR 112012013503A2
Authority
BR
Brazil
Prior art keywords
carboxyvinyl polymer
containing nanoparticle
compound
nanoparticle suspensions
compositions
Prior art date
Application number
BR112012013503A
Other languages
English (en)
Other versions
BR112012013503B8 (pt
BR112012013503B1 (pt
Inventor
Bahram Asgharian
Malay Ghosh
Masood A Chowhan
Wesley Wehsin Han
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43425837&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012013503(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of BR112012013503A2 publication Critical patent/BR112012013503A2/pt
Publication of BR112012013503B1 publication Critical patent/BR112012013503B1/pt
Publication of BR112012013503B8 publication Critical patent/BR112012013503B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Pigments, Carbon Blacks, Or Wood Stains (AREA)

Abstract

suspensões de nanopartículas contendo polímero de carboxivinila. a presente invenção refere-se geralmente a composições de suspensão que tem um polímero de carboxivinila tal como um carbômero, uma galactomanana tal como guar, e um composto de borato. um composto de particulado pouco sóluvel tal como nepafenaco também é incluído nas composições. o composto particulado pouco solúvel tem um tamanho de partícula pequeno para realçar biodisponibilidade do composto.
BR112012013503A 2009-12-03 2010-12-01 composição de suspensão oftálmica aquosa topicamente administrável, e método para manter sua viscosidade BR112012013503B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26636809P 2009-12-03 2009-12-03
US61/266,368 2009-12-03
PCT/US2010/058563 WO2011068872A2 (en) 2009-12-03 2010-12-01 Carboxyvinyl polymer-containing nanoparticle suspension

Publications (3)

Publication Number Publication Date
BR112012013503A2 true BR112012013503A2 (pt) 2016-06-07
BR112012013503B1 BR112012013503B1 (pt) 2021-04-20
BR112012013503B8 BR112012013503B8 (pt) 2021-05-25

Family

ID=43425837

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012013503A BR112012013503B8 (pt) 2009-12-03 2010-12-01 composição de suspensão oftálmica aquosa topicamente administrável, e método para manter sua viscosidade

Country Status (27)

Country Link
US (3) US8921337B2 (pt)
EP (3) EP2586426B1 (pt)
JP (3) JP5864433B2 (pt)
KR (2) KR101809484B1 (pt)
CN (1) CN102724965B (pt)
AR (2) AR080572A1 (pt)
AU (1) AU2010326099B2 (pt)
BR (1) BR112012013503B8 (pt)
CA (1) CA2781254C (pt)
CL (1) CL2012001402A1 (pt)
CY (1) CY1120585T1 (pt)
DK (3) DK2506831T3 (pt)
ES (3) ES2550942T3 (pt)
HK (3) HK1178802A1 (pt)
HR (2) HRP20140016T1 (pt)
HU (2) HUE025838T2 (pt)
LT (1) LT2965749T (pt)
MX (1) MX2012006231A (pt)
PL (3) PL2506831T3 (pt)
PT (3) PT2965749T (pt)
RS (2) RS57465B1 (pt)
RU (1) RU2571078C2 (pt)
SI (3) SI2506831T1 (pt)
TW (1) TWI486178B (pt)
UY (1) UY33081A (pt)
WO (1) WO2011068872A2 (pt)
ZA (1) ZA201203770B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435631B2 (en) * 2010-04-15 2013-05-07 Ppg Industries Ohio, Inc. Microporous material
ES2494140T3 (es) * 2010-07-20 2014-09-15 C-Ip S.A. Suspensión de compuesto de boro
TW201336527A (zh) * 2012-02-10 2013-09-16 Alcon Res Ltd 具增強的穩定性之水性藥學組成物
MX2015002208A (es) * 2012-08-31 2015-05-08 Bausch & Lomb Composiciones oftalmicas con acidos grasos omega-3.
WO2014207769A1 (en) 2013-06-27 2014-12-31 Mylan Laboratories Ltd Process for the preparation of nepafenac
US20150191647A1 (en) * 2014-01-07 2015-07-09 Trican Well Service Ltd. Stability of viscous fluids in low salinity environments
HUE041945T2 (hu) 2015-01-26 2019-06-28 Bausch & Lomb Szemészeti szuszpenzió készítmény
EP3310363A4 (en) * 2015-06-18 2019-02-13 Common Pharma, Inc ANTIMICROBIAL FORMULATIONS
US11730699B2 (en) 2018-02-21 2023-08-22 Alcon Inc. Lipid-based ophthalmic emulsion
TW201938141A (zh) * 2018-02-21 2019-10-01 瑞士商諾華公司 基於脂質的眼用乳劑

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3864183A (en) * 1972-11-21 1975-02-04 Tokyo Hat Method for producing pen core from filament tows
US4313949A (en) 1979-09-26 1982-02-02 A. H. Robins Company, Inc. Method of producing an inhibitory effect on blood platelet aggregation
IL80298A (en) 1986-10-14 1993-01-31 Res & Dev Co Ltd Eye drops
US5188826A (en) 1988-02-08 1993-02-23 Insite Vision Incorporated Topical ophthalmic suspensions
US5192535A (en) 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
US5461081A (en) 1989-09-28 1995-10-24 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5475034A (en) 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
FR2761959B1 (fr) * 1997-04-15 1999-05-21 Oreal Ensemble de conditionnement et d'application d'un produit fluide
JP3979783B2 (ja) 1997-07-29 2007-09-19 アルコン ラボラトリーズ インコーポレイテッド ガラクトマンナンポリマー及びホウ酸塩を含む眼科組成物
IT1306123B1 (it) 1999-04-02 2001-05-30 Technopharma Sa Soluzione oftalmica viscosizzata con azione detergente sulle lenti acontatto.
ITMI991453A1 (it) 1999-07-01 2001-01-01 Farmila Farma Milano Composizioni oftalmiche in forma di gel acquosi
EA006402B1 (ru) 1999-12-23 2005-12-29 Пфайзер Продактс Инк. Комбинация лекарства и целлюлозного полимера, повышающего концентрацию; способ введения лекарства и водный раствор (варианты)
PE20020146A1 (es) 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
AR031135A1 (es) 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
OA12624A (en) 2001-06-22 2006-06-12 Pfizer Prod Inc Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers.
US20050049291A1 (en) 2001-10-23 2005-03-03 Mukesh Kumar Process for the preparation of pharmaceutical compositions for topical delivery of cyclooxygenase-2-enzyme inhibitors
US7045121B2 (en) 2001-12-14 2006-05-16 Allergan, Inc. Ophthalmic compositions for lubricating eyes and methods for making and using same
TW200400055A (en) * 2002-02-22 2004-01-01 Pharmacia Corp Ophthalmic formulation with novel gum composition
TWI336257B (en) * 2003-06-13 2011-01-21 Alcon Inc Ophthalmic compositions containing a synergistic combination of three polymers
US7947295B2 (en) 2003-06-13 2011-05-24 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of two polymers
AU2004263149B2 (en) 2003-08-07 2010-08-19 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using same
FR2865648B1 (fr) 2004-02-03 2006-06-30 Philippe Perovitch Procede de diffusion de molecules insolubles en milieu aqueux et composition mettant en oeuvre ce procede
TWI358290B (en) 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
US20080145430A1 (en) 2004-12-08 2008-06-19 Santipharp Panmai Ophthalmic Nanoparticulate Formulation Of A Cyclooxygenase-2 Selective Inhibitor
TWI393567B (zh) 2005-03-31 2013-04-21 Bausch & Lomb 治療乾眼之組合物及相關之製造方法及使用方法
JP4257860B2 (ja) * 2005-04-19 2009-04-22 中得工業株式会社 化粧材の塗布具
JP4968954B2 (ja) 2005-05-10 2012-07-04 アルコン，インコーポレイテッド 活性成分、ポロキサマー界面活性剤もしくはメロキサポール界面活性剤およびグリコールを含有する懸濁処方物、ならびに眼の障害を処置するための医薬の製造のためのその使用
EP1906916B1 (en) * 2005-05-10 2008-10-29 Alcon Inc. Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders
BRPI0606172A2 (pt) 2005-06-08 2009-06-02 Targegen Inc métodos e composições para o tratamento de distúrbios oculares
JP5112669B2 (ja) * 2005-09-30 2013-01-09 富山化学工業株式会社 難溶性薬物のナノ微粒子を含有する水性懸濁液剤
US20070110812A1 (en) 2005-11-14 2007-05-17 Bausch & Lomb Incorporated Ophthalmic composition for dry eye therapy
US20070254841A1 (en) 2006-01-25 2007-11-01 Ophthalmic Research Associates, Inc. Formulations and methods for treating dry eye
US20070297981A1 (en) 2006-01-25 2007-12-27 Ousler George W Iii Formulations and methods for treating dry eye
US20080039398A1 (en) 2006-01-25 2008-02-14 Ousler George W Iii Formulations and methods for treating dry eye
US20070299124A1 (en) 2006-01-25 2007-12-27 Ousler George W Iii Formulations and methods for treating dry eye
WO2008002485A2 (en) 2006-06-23 2008-01-03 Alza Corporation Increased amorphous stability of poorly water soluble drugs by nanosizing
US20080260837A1 (en) 2007-04-20 2008-10-23 Qpharma, L.L.C. Physically stable aqueous suspensions of active pharmaceuticals
CA2687717A1 (en) 2007-05-24 2008-12-18 Aciex Therapeutics, Inc. Formulations and methods for treating dry eye
WO2009132294A1 (en) 2008-04-26 2009-10-29 Alcon Research, Ltd. Polymeric artificial tear system
JP4395189B1 (ja) * 2008-08-29 2010-01-06 株式会社ソリトン 塗布具
NZ594419A (en) 2009-02-05 2013-07-26 Alcon Res Ltd Process for purifying guar
JP5716960B2 (ja) * 2011-05-23 2015-05-13 オーベクス株式会社 塗布体用素材の製造方法及び塗布体用素材並びに塗布体及び塗布具

Also Published As

Publication number Publication date
PT2586426E (pt) 2015-11-17
EP2965749A1 (en) 2016-01-13
JP2013512912A (ja) 2013-04-18
BR112012013503B8 (pt) 2021-05-25
EP2506831A2 (en) 2012-10-10
CA2781254C (en) 2016-06-28
HRP20181337T1 (hr) 2018-10-19
RS53085B (en) 2014-06-30
KR20150063587A (ko) 2015-06-09
EP2586426B1 (en) 2015-09-23
ES2684752T3 (es) 2018-10-04
RU2571078C2 (ru) 2015-12-20
KR20120099269A (ko) 2012-09-07
SI2586426T1 (sl) 2015-11-30
US8921337B2 (en) 2014-12-30
BR112012013503B1 (pt) 2021-04-20
HK1217091A1 (zh) 2016-12-23
DK2506831T3 (da) 2013-12-16
AU2010326099A1 (en) 2012-07-19
CL2012001402A1 (es) 2014-03-28
AR080572A1 (es) 2012-04-18
AU2010326099B2 (en) 2013-03-07
PL2586426T3 (pl) 2016-01-29
US20170020818A1 (en) 2017-01-26
LT2965749T (lt) 2018-08-10
ES2441420T3 (es) 2014-02-04
WO2011068872A8 (en) 2013-04-04
WO2011068872A2 (en) 2011-06-09
DK2965749T3 (en) 2018-08-27
HK1170164A1 (en) 2013-02-22
ZA201203770B (en) 2013-08-28
SI2965749T1 (sl) 2018-09-28
AR122463A2 (es) 2022-09-14
HK1178802A1 (en) 2013-09-19
WO2011068872A3 (en) 2012-01-12
DK2586426T3 (en) 2015-11-23
PL2506831T3 (pl) 2014-05-30
CN102724965B (zh) 2015-08-05
PT2506831E (pt) 2014-01-08
HUE038821T2 (hu) 2018-11-28
KR101543613B1 (ko) 2015-08-11
RU2012127675A (ru) 2014-01-20
PT2965749T (pt) 2018-10-09
EP2965749B1 (en) 2018-05-23
TWI486178B (zh) 2015-06-01
KR101809484B1 (ko) 2017-12-15
PL2965749T3 (pl) 2018-10-31
US20110135743A1 (en) 2011-06-09
JP2016106155A (ja) 2016-06-16
CN102724965A (zh) 2012-10-10
RS57465B1 (sr) 2018-09-28
HUE025838T2 (en) 2016-04-28
HRP20140016T1 (hr) 2014-01-31
CA2781254A1 (en) 2011-06-09
EP2506831B1 (en) 2013-11-20
UY33081A (es) 2011-04-29
JP2015061886A (ja) 2015-04-02
MX2012006231A (es) 2012-07-03
EP2586426A1 (en) 2013-05-01
US9662398B2 (en) 2017-05-30
TW201129395A (en) 2011-09-01
US20150072011A1 (en) 2015-03-12
CY1120585T1 (el) 2019-07-10
JP5864433B2 (ja) 2016-02-17
SI2506831T1 (sl) 2014-01-31
JP6055849B2 (ja) 2016-12-27
ES2550942T3 (es) 2015-11-13

Similar Documents

Publication Publication Date Title
BR112012013503A2 (pt) suspensões de nanopartícula contendo polímero de carboxivinila
BR112013024953A2 (pt) processo para preparar as partículas de pigmento autoligantes, suspensão de partícula de pigmento autoligante, e, uso da suspensão de partícula de pigmento autoligante
TWD161131S (zh) 保溫瓶
TR201909389T4 (tr) Terapötik nanopartikülleri hazırlamaya yönelik proses.
MX2014010323A (es) Composiciones de ciclodextrina alquilada y procesos para preparar y utilizar las mismas.
BR112013028449A2 (pt) composições compreendendo partículas de hidrogel
MX2019000225A (es) Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
NZ742005A (en) Pharmaceutical nanoparticles showing improved mucosal transport
TWD160231S (zh) 車用前下保險桿蓋（一）
TWD158040S (zh) 連接器
BR112014013792A2 (pt) composição estabilizadora co-atritada, alimento, composição industrial, e, método para fazer a composição estabilizadora
MX349547B (es) Uso de marcadores raman para autentificacion de documentos de seguridad.
BR112015001414A2 (pt) composição antideriva
UA114655C2 (uk) Піридин-2-аміди, придатні як агоністи канабіноїдного рецептора 2
PH12015500887B1 (en) Alkylated cyclodextrin compositions and processes for preparing and using the same
PE20142325A1 (es) Composiciones derivadas de la quitosana
TR201903918T4 (tr) Bir dağıtım ajanı içeren bileşimler ve bunların hazırlanması.
IL239327A0 (en) Tetrazole derivatives in solid dispersion, preparations containing them and their uses
BR112014028066A2 (pt) polietilenoimina etoxilada, polímero de polietilenoimina etoxilada, e, uso de um polímero de polietilenoimina etoxilada
AR093813A1 (es) Composiciones en suspension de finafloxacina
TWD160224S (zh) 輪胎
RU2012129335A (ru) Медьсодержащий целлюлозный материал
RU2012124113A (ru) Наноструктурная водно-фосфоритная суспензия в качестве фосфорного удобрения под кукурузу
RU2012155811A (ru) Средство, обладающее антимикробной активностью
ES2721270T3 (es) Composiciones de profármaco de aripiprazol

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B25A Requested transfer of rights approved

Owner name: ALCON RESEARCH, LLC (US)

B25A Requested transfer of rights approved

Owner name: NOVARTIS AG (CH)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/12/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/12/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF